Joel Greenblatt's ACAD Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 18,441 shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $492,559, representing 0.00% of the portfolio. First purchased in 2016-Q4, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in ACAD, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2017, adding 38,843 shares. Largest reduction occurred in Q4 2017, reducing 38,843 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -24,726 | Reduce 57.28% | 18,441 | $26.71 |
| Q3 2025 | +25,560 | Add 145.17% | 43,167 | $21.34 |
| Q2 2025 | -16,467 | Reduce 48.33% | 17,607 | $21.57 |
| Q1 2025 | -35,892 | Reduce 51.30% | 34,074 | $16.61 |
| Q4 2024 | +34,240 | Add 95.84% | 69,966 | $18.35 |
| Q3 2024 | +5,129 | Add 16.76% | 35,726 | $15.38 |
| Q2 2024 | +30,597 | New Buy | 30,597 | $16.25 |
| Q2 2020 | -6,975 | Sold Out | 0 | $0.00 |
| Q1 2020 | -8,683 | Reduce 55.45% | 6,975 | $42.29 |
| Q4 2019 | -12,364 | Reduce 44.12% | 15,658 | $42.79 |
| Q3 2019 | +28,022 | New Buy | 28,022 | $36.01 |
| Q4 2017 | -38,843 | Sold Out | 0 | $0.00 |
| Q3 2017 | +38,843 | New Buy | 38,843 | $37.66 |
| Q1 2017 | -25,682 | Sold Out | 0 | $0.00 |
| Q4 2016 | +25,682 | New Buy | 25,682 | $28.85 |
Joel Greenblatt's ACADIA Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q4 2016, acquiring 25,682 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held ACADIA Pharmaceuticals Inc. (ACAD) for 15 quarters since Q4 2016.
Joel Greenblatt's largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q3 2017, adding 38,843 shares worth $1.46 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 18,441 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $492,559.
As of the Q4 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 69,966 shares, as reported at the end of Q4 2024.